| Title: |
One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration |
| Authors: |
C. A. Arcinue; F. Ma; L. Sharpsten; M. L. Gomez; W. R. Freeman; G. Barteselli |
| Contributors: |
C.A. Arcinue; F. Ma; G. Barteselli; L. Sharpsten; M.L. Gomez; W.R. Freeman |
| Publication Year: |
2015 |
| Collection: |
The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| Subject Terms: |
Settore MED/30 - Malattie Apparato Visivo |
| Description: |
PURPOSE: To evaluate 6-month and 1-year outcomes of every-8-weeks (Q8W) aflibercept in patients with resistant neovascular age-related macular degeneration (AMD). DESIGN: Retrospective, interventional, consecutive case series. METHODS: Retrospective review of patients with resistance (multiple recurrences or persistent exudation) to every-4-weeks (Q4W) ranibizumab or bevacizumab that were switched to Q8W aflibercept. RESULTS: Sixty-three eyes of 58 patients had a median of 13 (interquartile range [IQR], 7-22) previous anti-vascular endothelial growth factor (anti-VEGF) injections. At 6 months after changing to aflibercept, 60.3% of eyes were completely dry, which was maintained up to 1 year. The median maximum retinal thickness improved from 355 μm to 269 μm at 6 months (P < .0001) and 248 μm at 1 year (P < .0001). There was no significant improvement in ETDRS visual acuity at 6 months (P = .2559) and 1 year follow-up (P = .1081) compared with baseline. The mean difference in ETDRS visual acuity compared to baseline at 6 months was -0.05 logMAR (+2.5 letters) and 0.04 logMAR at 1 year (-2 letters). CONCLUSION: Sixty percent of eyes with resistant AMD while on Q4W ranibizumab or bevacizumab were completely dry after changing to Q8W aflibercept at the 6-month and 1-year follow-ups, but visual acuity did not significantly improve. Only a third of eyes needed to be switched from Q8W to Q4W aflibercept owing to persistence of fluid; Q8W dosing of aflibercept without the initial 3 monthly loading doses may be a good alternative in a select group of patients who may have developed ranibizumab or bevacizumab resistance. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/25461263; info:eu-repo/semantics/altIdentifier/wos/WOS:000350077100003; volume:159; issue:3; firstpage:1; lastpage:13; numberofpages:13; journal:AMERICAN JOURNAL OF OPHTHALMOLOGY; https://hdl.handle.net/2434/249038 |
| DOI: |
10.1016/j.ajo.2014.11.022 |
| Availability: |
https://hdl.handle.net/2434/249038; https://doi.org/10.1016/j.ajo.2014.11.022 |
| Rights: |
info:eu-repo/semantics/closedAccess |
| Accession Number: |
edsbas.F50436CC |
| Database: |
BASE |